Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy for prevention of recurrent infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial
Background: Recurrent Clostridioides difficile infection (rCDI) occurs in up to 35% of patients with CDI, and further recurrence is common. Fecal microbiota, live-jslm (RBL) is safe and effective for preventing rCDI in adults following antibiotic treatment for rCDI when administered rectally. There...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publishing
2025-05-01
|
| Colección: | Therapeutic Advances in Gastroenterology |
| Acceso en línea: | https://doi.org/10.1177/17562848251339697 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|